A South Korean company released a new product in Europe that uses siRNA (small interfering RNA) technology to address hair loss at the genetic level. It is called CosmeRNA
The company claim that CosmeRNA targets the protein that makes the androgen receptor, which binds to androgens. RNA codes for proteins that are made in the cells and the company claim is that the DHT receptors on the hair follicles are not expressed (that is the new DHT receptors aren’t created) hence the DHT molecule will not impact the hair follicle.
This product has yet to be released in the United States and has NOT been approved by the regulatory agency. Products not tested by a regulatory agency do not have robust safety and efficacy data.
This drug would fall under the cosmeceutical category which is not recognised by the regulatory body in America.
The important thing to note is that these kinds of drugs aren’t for hair loss. Similar drugs are used to treat nerve damage or a genetic liver disease (acute hepatic porphyria). As a result it remains unclear how effective this drug will be at stopping or reversing hair loss or what long term side effects are.
The technology of RNA interference has been tested in the lab, with varying levels of success. A significant issue has been side effects caused by an inflammatory response created upon delivery of these molecules.
There are so many products available for hair loss and most of them have very little supportive data. Seeing a medical hair loss specialist can help find the appropriate treatments for the unique needs of each individual.